



Announcement

NeuroSearch announces revised financial calendar for 2010

Copenhagen, 19 October 2010 – NeuroSearch (NEUR) today announced that the release date for the company's Q3 2010 interim report has been changed from 17 November to 18 November 2010.

Financial calendar for 2010

18 November 2010: Q3 2010 interim report

Patrik Dahlen
CEO

Contact persons:

Hanne Leth Hillman, Vice President, Director of Investor & Capital Market Relations,
telephone: +45 4460 8212 or +45 4017 5103

About NeuroSearch

NeuroSearch A/S is a leading CNS focused and European based biopharmaceutical company listed on NASDAQ OMX Copenhagen A/S (NEUR). The company's core business is development of novel drugs to treat diseases of the central nervous system, and the pipeline comprises eight products in clinical development (Phase I-III). These include Huntexil[®] (pridopidine), a unique orphan drug in Phase III development for the treatment of Huntington's disease, and tesofensine ready for Phase III development as a novel drug to treat obesity.

NeuroSearch is founded on a well-established drug discovery platform in the field of ion channels and monoamine transporters, ensuring the continuous production of novel preclinical development candidates. The company has strategic drug discovery and development alliances with Janssen Pharmaceutica and Eli Lilly as well as a licence collaboration with Abbott. Further, NeuroSearch has equity interests in a number of private companies in the Life Science industry.

